VADS DEBIO 1143-202 Pre-operative window-of-opportunity study of Debio 1143 with or without cisplatin in patients with resectable squamous cell carcinoma of the head and neck. Paris CHRISTOPHE LE TOURNEAU
VADS U31287-A-U203 / Patritumab RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 2 STUDY OF PATRITUMAB (U3-1287) IN COMBINATION WITH CETUXIMAB PLUS PLATINUM-BASED THERAPY IN FIRST LINE SETTING IN SUBJECTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK. Paris CHRISTOPHE LE TOURNEAU
VADS TOPNIVO - ORL09 A Safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN). Paris CHRISTOPHE LE TOURNEAU
VADS UP-STREAM ( EORTC 1559-HNCG) A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. Paris CHRISTOPHE LE TOURNEAU
Pédiatrie Sarcomes CombinaiR3 First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years Paris VALERIE LAURENCE
Appareil Digestif SCARCE (C17-02 PRODIGE 60) A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma Paris
Pédiatrie Sarcomes SARCOME 13 (Pédiatrie) Multicentre, Randomised, Phase 2 Trial of Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (Metastatic Osteosarcoma at Diagnosis or Localised Disease With Poor Histological Response) Paris HELENE PACQUEMENT
Sein métastatique triple négatif CLAG525B2101 A phase II open-label, randomized, three-arm, multicenter study of LAG525 given in combination with spartalizumab (PDR001), or with spartalizumab and carboplatin, or with carboplatin, as first or second line therapy in patients with advanced triple-negative breast cancer. Paris JEAN-YVES PIERGA
Pédiatrie Sarcomes E7080-G000-230 OLIE A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of;Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in;Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma Paris ISABELLE AERTS
VADS ICING ORL A Phase II Trial Assessing Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-ß and PD-L1, in a Pre-operative Setting for Resectable and Untreated Head and Neck Squamous Cell Carcinoma Paris CHRISTOPHE LE TOURNEAU, CHRISTOPHE LE TOURNEAU